Referred to the House Committee on Energy and Commerce.
The bill creates a new FDA authority to designate certain prescription drugs as "priority nonprescription drugs" to expedite development and review for over-the-counter use. Sponsors may request designation; the FDA must decide within 60 days and may provide accelerated interactions, senior review staff, a project lead, and use of efficient trial designs including real-world evidence.
Progressives focus on equity, safety, and affordability concerns.
Relative to its intended legislative type, this bill creates a clear statutory framework to designate and facilitate expedited development and review of certain nonprescription drugs.
The bill creates a new FDA authority to designate certain prescription drugs as "priority nonprescription drugs" to expedite development and review for over-the-counter use.
Sponsors may request designation; the FDA must decide within 60 days and may provide accelerated interactions, senior review staff, a project lead, and use of efficient trial designs including real-world evidence.
Eligibility covers novel nonprescription indications, new molecular entities, or active ingredients never previously OTC, excluding REMS-required drugs and controlled substances.
Content is technical and low-controversy, improving odds; success depends on legislative vehicle, timing, and stakeholder support.
Relative to its intended legislative type, this bill creates a clear statutory framework to designate and facilitate expedited development and review of certain nonprescription drugs. It integrates with existing FD&C provisions, sets eligibility criteria, prescribes a designation decision deadline, requires publication of a conditions list with public comment, mandates a 4-year report to Congress, and includes a sunset date—providing meaningful structural elements for implementation.
Progressives focus on equity, safety, and affordability concerns.
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressives focus on equity, safety, and affordability concerns.
Generally favorable to increased access to proven medicines outside clinics, but cautious about safety, equity, and affordability.
The explicit preservation of evidentiary standards and REMS/controlled-substance exclusions reduce safety concerns, yet questions remain about post-market surveillance and who benefits.
Will look for safeguards for vulnerable populations and commitments to ensure affordable OTC pricing.
Supportive of a targeted, time-limited modernization that speeds safe OTC availability while keeping evidence standards intact.
Appreciates procedural deadlines, public comment on conditions, reporting to Congress, and sunset clause.
Wants clarity on FDA resource needs and measurable outcomes before expanding further.
Generally favorable because it reduces regulatory delay and increases consumer access and choice, while remaining sponsor-driven and time-limited.
May prefer even lighter regulatory pathways, but will welcome exclusions for REMS and controlled substances and the preservation of evidence requirements.
Some fiscal conservatives may seek assurances about administrative costs.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Content is technical and low-controversy, improving odds; success depends on legislative vehicle, timing, and stakeholder support.
The bill has not accumulated any surfaced votes yet.
Progressives focus on equity, safety, and affordability concerns.
Content is technical and low-controversy, improving odds; success depends on legislative vehicle, timing, and stakeholder support.
Relative to its intended legislative type, this bill creates a clear statutory framework to designate and facilitate expedited development and review of certain nonprescription drugs. It integrates with existing FD&C pr…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.